Page last updated: 2024-08-21

azomycin and Atypical Mycobacterial Infection, Disseminated

azomycin has been researched along with Atypical Mycobacterial Infection, Disseminated in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	6 (75.00)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
He, W; Li, F; Shen, C; Wang, S; Wang, Y; Xia, H; Zhao, B; Zhao, Y; Zheng, H	1
Jo, KW; Nam, GB; Shim, TS; Yoon, HY	1
Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P	1
Baillie, L; Baptista, R; Beckmann, M; Fazakerley, DM; Mur, LAJ	1
Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD	1
Daley, CL; Huh, HJ; Jeon, K; Jhun, BW; Kim, DH; Kim, SY; Koh, WJ; Kwon, OJ; Lee, NY; Moon, SM; Shin, SJ	1
Chopra, S; Dasgupta, A; De Groote, MA; Soni, I	1
Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C	1

Reviews

2 review(s) available for azomycin and Atypical Mycobacterial Infection, Disseminated

Article	Year
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. Current opinion in pulmonary medicine, 2019, Volume: 25, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles	2019
Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria. Journal of medical microbiology, 2016, Volume: 65, Issue:1 Topics: Adamantane; Aminopyridines; Anti-Bacterial Agents; Azepines; Benzamides; Clinical Trials as Topic; Diarylquinolines; Drug Discovery; Ethylenediamines; Fluoroquinolones; Humans; Minocycline; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Piperazines; Spiro Compounds; Thiazines; Tigecycline; Uridine	2016

Article

Year

New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.

Current opinion in pulmonary medicine, 2019, Volume: 25, Issue:3

Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles

2019

Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria.

Journal of medical microbiology, 2016, Volume: 65, Issue:1

Topics: Adamantane; Aminopyridines; Anti-Bacterial Agents; Azepines; Benzamides; Clinical Trials as Topic; Diarylquinolines; Drug Discovery; Ethylenediamines; Fluoroquinolones; Humans; Minocycline; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Piperazines; Spiro Compounds; Thiazines; Tigecycline; Uridine

2016

Other Studies

6 other study(ies) available for azomycin and Atypical Mycobacterial Infection, Disseminated

Article	Year
Antimicrobial agents and chemotherapy, 2022, 01-18, Volume: 66, Issue:1 Topics: Humans; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria	2022
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 09-01, Volume: 21, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult	2017
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions. Journal of medical microbiology, 2018, Volume: 67, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin	2018
Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Scientific reports, 2018, 03-23, Volume: 8, Issue:1 Topics: Antitubercular Agents; Gas Chromatography-Mass Spectrometry; Humans; Metabolic Networks and Pathways; Metabolome; Metabolomics; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Nitroimidazoles	2018
Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:8 Topics: Anti-Bacterial Agents; Antitubercular Agents; Diarylquinolines; Humans; Macrolides; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium avium Complex; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles	2019
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors	2006